AstraZeneca (AZN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AZN AstraZeneca

Watchlist

66.300
-0.330-0.50%

Close Dec 24 13:00 ET

66.016
-0.284-0.43%

Post 17:01 ET

205.57BMarket Cap31.95P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

AstraZeneca, Daiichi Sankyo Have Voluntarily Withdrawn a Dato-DXd MAA in EU
Yahoo FinanceDec 25 05:10 ET
Quantum Computing Stocks Soar: How to Capture the Investment Opportunities?
Moomoo News AUDec 25 01:37 ET
AstraZeneca PLC ADR Underperforms Tuesday When Compared To Competitors
MarketWatchDec 24 17:29 ET
Achilles Therapeutics Transfers TRACERx Data and MAP Assets to AstraZeneca in $12M Agreement
Quiver QuantitativeDec 24 09:41 ET
Express News | Achilles Therapeutics Sells TRACERx And MAP Assets To AstraZeneca For $12M, Transferring Tumor Data And Samples; Concludes Strategic Review With Plans For Workforce And Board Reductions
BenzingaDec 24 09:31 ET
Press Release: Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
Dow JonesDec 24 09:30 ET

Comments

Meltyy

Dec 17 01:56

📌 1 PDUFA this weekand 6 more upcoming this month! 🚀

🔔 This Week’s PDUFA:
$Ionis Pharmaceuticals (IONS.US)$ : 🤔
⇨ IONIS-APOCIII-LRx (Olezarsen)
‣ FCS (Familial chylomicronemia syndrome)
‣ PDUFA: 12/19/24 (NDA)
🗓️ Last Week’s PDUFA Decisions:
$Checkpoint Therapeutics (CKPT.US)$ : Approved 12/13/24 ✅
⇨ UNLOXCYT (cosibelimab-ipdl)
‣ metastatic or locally advanced cSCC (cutaneous squamous cell carcinoma)
‣ PDUFA: 12/28/24 (resubmitted BLA)
$Neurocrine Biosciences (NBIX.US)$ : Approved 12/13/24 ✅
⇨ CRENESSITY™ (crin...

10xStockPicks

Dec 15 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...